These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15793554)

  • 41. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis but do not necessarily predict treatment failure.
    Golberg O; Osborne JE; Hutchinson PE
    Br J Dermatol; 2011 Feb; 164(2):459-60. PubMed ID: 20973773
    [No Abstract]   [Full Text] [Related]  

  • 42. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the efficacy of acitretin therapy for nail psoriasis.
    Tosti A; Ricotti C; Romanelli P; Cameli N; Piraccini BM
    Arch Dermatol; 2009 Mar; 145(3):269-71. PubMed ID: 19289755
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The appearance of pustular psoriasis during antitumor necrosis factor therapy.
    Goncalves DP; Laurindo I; Scheinberg MA
    J Clin Rheumatol; 2006 Oct; 12(5):262. PubMed ID: 17023816
    [No Abstract]   [Full Text] [Related]  

  • 47. Infliximab in the treatment of psoriasis in patients previously treated with etanercept.
    Haitz KA; Kalb RE
    J Am Acad Dermatol; 2007 Jul; 57(1):120-5. PubMed ID: 17482715
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatosplenic T-cell lymphomas and therapy with TNF-alpha-blocking biologics: a risk for psoriasis patients?
    Beyer M; Steinhoff M; Anagnostopoulos I; Assaf C; Sterry W
    J Dtsch Dermatol Ges; 2009 Mar; 7(3):191-4. PubMed ID: 19192165
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Our experience with infliximab in reclacitrant cases of psoriasis].
    Pereiro M; González-Vilas D; Sánchez-Aguilar D; Toribio J
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():43-7. PubMed ID: 19080991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ustekinumab for rapid treatment of nail psoriasis.
    Rallis E; Kintzoglou S; Verros C
    Arch Dermatol; 2010 Nov; 146(11):1315-6. PubMed ID: 21079083
    [No Abstract]   [Full Text] [Related]  

  • 52. Alefacept in the treatment of psoriatic nail disease: a small case series.
    Cassetty CT; Alexis AF; Shupack JL; Strober BE
    J Am Acad Dermatol; 2005 Jun; 52(6):1101-2. PubMed ID: 15928640
    [No Abstract]   [Full Text] [Related]  

  • 53. Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients.
    Vitiello M; Tosti A; Abuchar A; Zaiac M; Kerdel FA
    Int J Dermatol; 2013 Mar; 52(3):358-62. PubMed ID: 23330782
    [No Abstract]   [Full Text] [Related]  

  • 54. [Psoriasis induced by infliximab. Reply].
    Costa Romero M; Coto Segura P; Santos-Juanes Jiménez J
    An Pediatr (Barc); 2009 Jun; 70(6):608. PubMed ID: 19464969
    [No Abstract]   [Full Text] [Related]  

  • 55. [Psoriasis induced by infliximab. Reply].
    Avila Alvarez A; Solar Boga A
    An Pediatr (Barc); 2009 Nov; 71(5):462. PubMed ID: 19736052
    [No Abstract]   [Full Text] [Related]  

  • 56. Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1.
    Kristensen LE; Soliman AM; Papp K; Merola JF; Barcomb L; Wang Z; Eldred A; Behrens F
    J Eur Acad Dermatol Venereol; 2022 May; 36(5):e389-e392. PubMed ID: 35032356
    [No Abstract]   [Full Text] [Related]  

  • 57. Recalcitrant psoriatic onycho-pachydermo-periostitis successfully treated with guselkumab.
    Brunasso AMG; Sola S; Massone C
    Clin Exp Dermatol; 2021 Jun; 46(4):789-791. PubMed ID: 33619743
    [No Abstract]   [Full Text] [Related]  

  • 58. Elevation of serum KL-6 levels during treatment with tumor necrosis factor-α inhibitor in patients with psoriasis.
    Mabuchi T; Yamaoka H; Kawai M; Ota T; Ozawa A
    J Dermatol; 2014 Dec; 41(12):1136-7. PubMed ID: 25388751
    [No Abstract]   [Full Text] [Related]  

  • 59. Severe acral contractures and nail loss in a patient with mechano-bullous Epidermolysis bullosa acquisita.
    Meissner C; Hoefeld-Fegeler M; Vetter R; Bellutti M; Vorobyev A; Gollnick H; Leverkus M
    Eur J Dermatol; 2010; 20(4):543-4. PubMed ID: 20522419
    [No Abstract]   [Full Text] [Related]  

  • 60. Psoriasis confined to the nails.
    Schmults CA
    Dermatol Online J; 2003 Oct; 9(4):7. PubMed ID: 14594580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.